Young adults continue to have high rates of uninsurance despite gains made under Obamacare. » Read More
Gilead Sciences fell nearly 8 percent, dragging down the S&P 500’s health care sector.
Quest Diagnostics said it has received emergency authorization from U.S. regulators to sell the first commercially developed diagnostic test for Zika.
Diagnostic test maker Alere said it has rejected a request by Abbott Laboratories to terminate the $5.8 billion deal to buy Alere for a breakup fee.
A huge Hewlett Packard Enterprise project hopes to use massive data sets to better craft medical treatments and medicines for patients.
If there are inflation winds in the air, it would be hard to tell by worker paychecks.
Aetna CEO and Chairman Mark Bertolini talked to CNBC about earnings, drug prices and needed changes to Obamacare.
The pharmacy benefits manager is looking to partner with retail pharmacies that do the best job at keeping diabetes patients healthy.
Abbott Labs said it agreed to St. Jude Medical for $25 billion to add heft to its heart and neurological devices business.
Creating Facebook was a bold move, but CEO Mark Zuckerberg just proposed what he said is an even bolder one.
Drugmaker AbbVie said it would buy privately held oncology company Stemcentrx in a deal valued at $5.8 billion in cash and stock.
Boston Scientific rose after the firm reported better-than-expected quarterly results.
Increasing sales of new products and growing demand for vaccines and consumer healthcare goods helped lift GlaxoSmithKline's sales figures 8 percent.
The ex-Citigroup chair and his family foundation have donated $185M to the UCSF to establish the UCSF Weill Institute for Neurosciences.
The 300 million pain prescriptions written last year equal a $24B market, but it's not a market evenly divided around the globe.
Valeant, whose stock has plunged amid probes into its drug pricing, is too mired in debt to recover, an analyst said.
BP's message to other oil companies in the first quarter was loud and clear, CNBC's Jim Cramer says.
Get the best of CNBC in your inbox